Literature DB >> 32789840

First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases.

Ewa Dziewięcka1, Mateusz Winiarczyk2, Matylda Gliniak2, Monika Kaciczak2, Sylwia Wiśniowska-Śmiałek3, Aleksandra Karabinowska3, Katarzyna Holcman3, Magdalena Kostkiewicz3, Marta Hlawaty3, Agata Leśniak-Sobelga3, Piotr Podolec3, Paweł Rubiś3.   

Abstract

Entities:  

Year:  2020        PMID： 32789840      PMCID： PMC8078977          DOI： 10.5603/CJ.a2020.0100

Source DB:  PubMed          Journal:  Cardiol J        ISSN： 1898-018X            Impact factor:   2.737


× No keyword cloud information.
  10 in total

1.  Association of Cardiometabolic Multimorbidity With Mortality.

Authors:  Emanuele Di Angelantonio; Stephen Kaptoge; David Wormser; Peter Willeit; Adam S Butterworth; Narinder Bansal; Linda M O'Keeffe; Pei Gao; Angela M Wood; Stephen Burgess; Daniel F Freitag; Lisa Pennells; Sanne A Peters; Carole L Hart; Lise Lund Håheim; Richard F Gillum; Børge G Nordestgaard; Bruce M Psaty; Bu B Yeap; Matthew W Knuiman; Paul J Nietert; Jussi Kauhanen; Jukka T Salonen; Lewis H Kuller; Leon A Simons; Yvonne T van der Schouw; Elizabeth Barrett-Connor; Randi Selmer; Carlos J Crespo; Beatriz Rodriguez; W M Monique Verschuren; Veikko Salomaa; Kurt Svärdsudd; Pim van der Harst; Cecilia Björkelund; Lars Wilhelmsen; Robert B Wallace; Hermann Brenner; Philippe Amouyel; Elizabeth L M Barr; Hiroyasu Iso; Altan Onat; Maurizio Trevisan; Ralph B D'Agostino; Cyrus Cooper; Maryam Kavousi; Lennart Welin; Ronan Roussel; Frank B Hu; Shinichi Sato; Karina W Davidson; Barbara V Howard; Maarten J G Leening; Maarten Leening; Annika Rosengren; Marcus Dörr; Dorly J H Deeg; Stefan Kiechl; Coen D A Stehouwer; Aulikki Nissinen; Simona Giampaoli; Chiara Donfrancesco; Daan Kromhout; Jackie F Price; Annette Peters; Tom W Meade; Edoardo Casiglia; Debbie A Lawlor; John Gallacher; Dorothea Nagel; Oscar H Franco; Gerd Assmann; Gilles R Dagenais; J Wouter Jukema; Johan Sundström; Mark Woodward; Eric J Brunner; Kay-Tee Khaw; Nicholas J Wareham; Eric A Whitsel; Inger Njølstad; Bo Hedblad; Sylvia Wassertheil-Smoller; Gunnar Engström; Wayne D Rosamond; Elizabeth Selvin; Naveed Sattar; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2015-07-07       Impact factor: 56.272

2.  Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry.

Authors:  Abhinav Sharma; Xin Zhao; Bradley G Hammill; Adrian F Hernandez; Gregg C Fonarow; G Michael Felker; Clyde W Yancy; Paul A Heidenreich; Justin A Ezekowitz; Adam D DeVore
Journal:  Circ Heart Fail       Date:  2018-06       Impact factor: 8.790

3.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.

Authors:  Stephen D Wiviott; Itamar Raz; Marc S Sabatine
Journal:  N Engl J Med       Date:  2019-05-09       Impact factor: 91.245

Review 4.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

Authors:  Francesco Cosentino; Peter J Grant; Victor Aboyans; Clifford J Bailey; Antonio Ceriello; Victoria Delgado; Massimo Federici; Gerasimos Filippatos; Diederick E Grobbee; Tina Birgitte Hansen; Heikki V Huikuri; Isabelle Johansson; Peter Jüni; Maddalena Lettino; Nikolaus Marx; Linda G Mellbin; Carl J Östgren; Bianca Rocca; Marco Roffi; Naveed Sattar; Petar M Seferović; Miguel Sousa-Uva; Paul Valensi; David C Wheeler
Journal:  Eur Heart J       Date:  2020-01-07       Impact factor: 29.983

5.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply.

Authors:  John J V McMurray; Kieran F Docherty; Pardeep S Jhund
Journal:  N Engl J Med       Date:  2020-03-05       Impact factor: 91.245

6.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

7.  Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.

Authors:  Mattie Lenzen; Lars Ryden; John Ohrvik; Malgorzata Bartnik; Klas Malmberg; Wilma Scholte Op Reimer; Maarten L Simoons
Journal:  Eur Heart J       Date:  2006-11-07       Impact factor: 29.983

8.  Effect of blood glucose levels on prognosis in acute myocardial infarction in patients with and without diabetes, undergoing percutaneous coronary intervention.

Authors:  Mariusz Gasior; Damian Pres; Gabriela Stasik-Pres; Piotr Lech; Marek Gierlotka; Michał Hawranek; Krzysztof Wilczek; Bozena Szyguła-Jurkiewicz; Andrzej Lekston; Zbigniew Kalarus; Krzysztof Strojek; Janusz Gumprecht; Lech Poloński
Journal:  Cardiol J       Date:  2008       Impact factor: 2.737

9.  Clinical outcome of patients with diabetes presenting with ST-elevation myocardial infarction and treated with concomitant use of glycoprotein IIb/IIIa inhibitors.

Authors:  Stefan Kralev; Barbara Krause; Theano Papavassiliu; Siegfried Lang; Dariusch Haghi; Thorsten Kälsch; Carl-Erik Dempfle; Martin Borggrefe; Tim Süselbeck
Journal:  Cardiol J       Date:  2009       Impact factor: 2.737

10.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Authors:  David Fitchett; Bernard Zinman; Christoph Wanner; John M Lachin; Stefan Hantel; Afshin Salsali; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  Eur Heart J       Date:  2016-01-26       Impact factor: 29.983
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.